There are currently 1572 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
NCT05948826
Recruiting
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Advanced Solid Tumor, Colorectal Cancer
Register for Updates
TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals
NCT05275998
Recruiting
TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC-07-523LS is a monoclonal antibody that binds to HIV. Both interfere with HIV entry. This study is designed to test various doses of the combination of the antibodies for safety and pharmacokinetics in suppressed subjects on cART. Once dosing is established based on safety and PK, the optimally dosed combinations will be assessed as maintenance therapy in HIV infected suppressed individuals discontinuing oral cART f... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
03/11/2024
Locations: North Texas Infectious Disease Consultants, Dallas, Texas
Conditions: HIV-1-infection
Register for Updates
Pivotal Observational CHLOE Study
NCT06111365
Recruiting
This pivotal study is an observational, prospective assessment, multi-center, databank based, clinical study aimed to evaluate the performance of CHLOE™ algorithm in prediction of blastocyst formation. Day 3 morphological grading will be performed by three clinical embryologists (hereafter "Assessors"), who will use standard embryo grading assessment techniques and will be blinded to the CHLOE™ information and to the actual blastocyte status (Yes/No). Five independent embryologists (hereafter... Read More
Gender:
Female
Ages:
Between 18 years and 120 years
Trial Updated:
03/10/2024
Locations: Dallas Fertility Center, Dallas, Texas
Conditions: IVF
Register for Updates
Pedi-Cap CO2 Detector for Face-mask Ventilation in the Delivery Room
NCT06258187
Recruiting
The goal of this study is to determine if using a Pedi-Cap (a type of colorimetric carbon dioxide detector) during face mask ventilation (PPV) for newborn infants in the delivery room will lower the time of PPV needed. A group of nurses, doctors, and respiratory therapists, called the neonatal resuscitation team, will either use or not use the Pedi-Cap during face mask PPV for infants born at ≥30 weeks' gestation. A randomization generator will assign each month either using the Pedi-Cap or not... Read More
Gender:
All
Ages:
30 weeks and above
Trial Updated:
03/10/2024
Locations: Parkland Health, Dallas, Texas
Conditions: Neonatal Resuscitation, Neonatal Disease
Register for Updates
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study
NCT05327686
Recruiting
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: UT Southwestern Simmons Cancer Center - RedBird, Dallas, Texas +1 locations
Conditions: Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
Register for Updates
HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Cancer
NCT04403620
Recruiting
There is a strong radiobiological and economic rationale for hypofractionated radiation therapy in head and neck cancer. Phase 1 of the trial aims to assess the acute toxicity and tolerability of hypofractionated radiation therapy in the post-operative setting, and to determine the dose/fractionation for Phase 2. Phase 2 aims to establish non-inferiority of swallowing-related quality of life and to assess the toxicity and efficacy of hypofractionated radiation therapy compared to conventionally... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Squamous Cell Carcinoma of Head and Neck
Register for Updates
A Phase II Trial of Poly-ICLC for Low-Grade Gliomas
NCT04544007
Recruiting
This is a phase II, prospective, longitudinal, multi-center trial of poly-ICLC (Hiltonol ®) treatment for progressive low-grade gliomas in pediatric patients with NF1. The primary objective is to evaluate the efficacy of poly-ICLC in pediatric NF1 patients with progressive low-grade glioma (LGG) as measured by objective tumor response rate (CR+PR) within the first 48 weeks (12 cycles) of therapy. There will also be secondary and exploratory objectives listed in the detailed description below.
Gender:
All
Ages:
22 years and below
Trial Updated:
03/08/2024
Locations: Childrens Medical Center - Univ. of Texas SW (Site 917), Dallas, Texas
Conditions: NF1, Low-grade Glioma
Register for Updates
PSMA PET Response Guided SabR in High Risk Pca
NCT06044857
Recruiting
Sequential cohort evaluation of ideal timing of imaging and treatment spacing to discern maximal PSMA (Prostate specific membrane antigen) PET (Positron Emission Tomography) response (PSMA-11 68Ga, Illucix) for adaptation of dominant intra-prostatic lesion tumor boost dose
Gender:
Male
Ages:
Between 18 years and 99 years
Trial Updated:
03/08/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas +1 locations
Conditions: Prostate Adenocarcinoma
Register for Updates
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO)
NCT02530073
Recruiting
The rationale for fetal therapy in severe congenital diaphragmatic hernia (CDH) is to restore adequate lung growth for neonatal survival.
Gender:
Female
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Medical City Children's Hospital, Dallas, Texas
Conditions: Congenital Diaphragmatic Hernias
Register for Updates
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
NCT04551131
Recruiting
This study is a multi-site Phase Ib/II, 2-arm non-randomized clinical trial to determine the efficacy and tolerability of a response-adapted regimen combining ruxolitinib, dexamethasone, and etoposide as Frontline therapy for patients with newly diagnosed hemophagocytic lymphohistiocytosis (HLH) or as Salvage therapy for patients with relapsed/refractory HLH. Primary Objective To determine the efficacy and tolerability of a response-adapted ruxolitinib-containing regimen for patients with newl... Read More
Gender:
All
Ages:
Between 6 weeks and 22 years
Trial Updated:
03/08/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Hemophagocytic Lymphohistiocytosis
Register for Updates
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
NCT05394103
Recruiting
Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901 as a monotherapy and in combination with pembrolizumab
Gender:
All
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Advanced Cancer, Metastatic Cancer
Register for Updates
Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease
NCT05956626
Recruiting
This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease. This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 42 subjects.
Gender:
All
Ages:
Between 6 years and 65 years
Trial Updated:
03/07/2024
Locations: Retina Foundation of the Southwest, Dallas, Texas
Conditions: Stargardt Disease
Register for Updates